Consistent with our finding, CLDN3 was previously reported to express at a reduced level in EBVaGC [24,25], while DPP4 is an androgen receptor-induced tumor suppressor gene that was downregulated in some cases of prostate cancer. The gene discussed is DPP4; the disease is prostate carcinoma.